The decision to discontinue the program was based on data indicating “insufficient efficacy in the target population.” Johnson & Johnson is ending the phase 3 VENTURA clinical development program ...

Johnson & Johnson (J&J) is dropping its Phase III major depressive disorder (MDD) programme for aticaprant due to ‘insufficient efficacy in the target population’. The VENTURA programme, evaluating ...

Please provide your email address to receive an email when new articles are posted on . The study included 166 adults with major depressive disorder randomized to receive aticaprant or placebo. At 6 ...

Johnson & Johnson JNJ decided to discontinue the Phase 3 VENTURA development program, which is evaluating aticaprant as an adjunctive treatment for major depressive disorder (MDD). Though data from ...

On Friday, Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment for ...

Johnson & Johnson has decided to halt the development of selective kappa opioid receptor (KOR) antagonist aticaprant as a treatment for major depressive disorder (MDD), blowing a hole in its ...

Johnson & Johnson has added to the opioid kappa blues. Months after Neumora reported a phase 3 flop, J&J has stopped development of its rival drug candidate aticaprant as an adjunctive treatment for ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Johnson & Johnson is terminating some research for an ...

Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial keeps that hope alive. Topline ...